Related Experiment Video
Updated: Dec 22, 2025

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Reduction in Baseline CD4 Count Testing Following Human Immunodeficiency Virus "Treat All" Adoption in Uganda
Esther Nasuuna1, Mark W Tenforde2,3, Alex Muganzi1
1Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Insights
CD4 testing rates in Uganda dropped significantly after the "Treat All" policy. Many patients still present with advanced HIV disease, indicating a critical gap in care despite policy changes.
Area of Science:
- Public Health
- Infectious Diseases
- HIV/AIDS Research
Background:
- The
Purpose of the Study:
- To analyze trends in CD4 testing rates and the prevalence of advanced HIV disease in Uganda following the
Main Methods:
- Retrospective analysis of CD4 testing data and patient demographics.
- Examination of HIV disease staging at the time of diagnosis or testing.
Main Results:
- CD4 testing rates decreased from 73% in 2013 to 21% in 2018.
- In 2018, 24% of tested individuals had advanced HIV disease (CD4 < 200 cells/µL).
- 83% of those with advanced disease presented with WHO stage I/II disease.
Conclusions:
- A dramatic decline in CD4 testing occurred despite the
Abstract:
Baseline CD4 testing rates declined from 73% to 21% between 2013 and 2018 with adoption of "Treat All" in Uganda. Advanced human immunodeficiency virus (HIV) disease (CD4 count < 200 cells/µL) remained common (24% of those tested in 2018, 83% of whom had World Health Organization stage I/II disease). Despite frequent presentation with advanced HIV disease, CD4 testing has declined dramatically.
Related Concept Videos
Retrovirus Life Cycles
Immunodeficiency Diseases
There are three main causes of immunodeficiency...

